TY - JOUR
T1 - Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis
AU - Fitzgerald, Kathryn C.
AU - O'Reilly, Éilis J.
AU - Falcone, Guido J.
AU - McCullough, Marjorie L.
AU - Park, Yikyung
AU - Kolonel, Laurence N.
AU - Ascherio, Alberto
N1 - Publisher Copyright:
Copyright 2014 American Medical Association. All rights reserved.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - IMPORTANCE: Amyotrophic lateral sclerosis (ALS) is a severe progressive disease that cannot be prevented or cured. Diet-derived long-chain polyunsaturated fatty acids (PUFAs) are incorporated in brain lipids and modulate oxidative and inflammatory processes and could thus affect ALS risk and progression. OBJECTIVE: To examine the association between ω-6 and ω-3 PUFA consumption and ALS risk. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal analyses based on 1 002 082 participants (479 114 women and 522 968 men) in 5 prospective cohorts: the National Institutes of Health-AARP Diet and Health Study, the Cancer Prevention Study II Nutrition Cohort, the Health Professionals Follow-up Study, the Multiethnic Cohort Study, and the Nurses' Health Study. Diet was assessed via food frequency questionnaire developed or modified for each cohort. Participants were categorized into cohort-specific quintiles of intake of energy-adjusted dietary variables. MAIN OUTCOMES AND MEASURES: Cohort-specific multivariable-adjusted risk ratios (RRs) of ALS incidence or death estimated by Cox proportional hazards regression and pooled using random-effects methods. RESULTS: A total of 995 ALS cases were documented during the follow-up. A greater ω-3 PUFA intake was associated with a reduced risk for ALS. The pooled, multivariable-adjusted RR for the highest to the lowest quintile was 0.66 (95%CI, 0.53-0.81; P < .001 for trend). Consumption of both α-linolenic acid (RR, 0.73; 95%CI, 0.59-0.89; P = .003 for trend) and marine ω-3 PUFAs (RR, 0.84; 95%CI, 0.65-1.08; P = .03 for trend) contributed to this inverse association. Intakes of ω-6 PUFA were not associated with ALS risk. CONCLUSIONS AND RELEVANCE: Consumption of foods high in ω-3 PUFAs may help prevent or delay the onset of ALS.
AB - IMPORTANCE: Amyotrophic lateral sclerosis (ALS) is a severe progressive disease that cannot be prevented or cured. Diet-derived long-chain polyunsaturated fatty acids (PUFAs) are incorporated in brain lipids and modulate oxidative and inflammatory processes and could thus affect ALS risk and progression. OBJECTIVE: To examine the association between ω-6 and ω-3 PUFA consumption and ALS risk. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal analyses based on 1 002 082 participants (479 114 women and 522 968 men) in 5 prospective cohorts: the National Institutes of Health-AARP Diet and Health Study, the Cancer Prevention Study II Nutrition Cohort, the Health Professionals Follow-up Study, the Multiethnic Cohort Study, and the Nurses' Health Study. Diet was assessed via food frequency questionnaire developed or modified for each cohort. Participants were categorized into cohort-specific quintiles of intake of energy-adjusted dietary variables. MAIN OUTCOMES AND MEASURES: Cohort-specific multivariable-adjusted risk ratios (RRs) of ALS incidence or death estimated by Cox proportional hazards regression and pooled using random-effects methods. RESULTS: A total of 995 ALS cases were documented during the follow-up. A greater ω-3 PUFA intake was associated with a reduced risk for ALS. The pooled, multivariable-adjusted RR for the highest to the lowest quintile was 0.66 (95%CI, 0.53-0.81; P < .001 for trend). Consumption of both α-linolenic acid (RR, 0.73; 95%CI, 0.59-0.89; P = .003 for trend) and marine ω-3 PUFAs (RR, 0.84; 95%CI, 0.65-1.08; P = .03 for trend) contributed to this inverse association. Intakes of ω-6 PUFA were not associated with ALS risk. CONCLUSIONS AND RELEVANCE: Consumption of foods high in ω-3 PUFAs may help prevent or delay the onset of ALS.
UR - http://www.scopus.com/inward/record.url?scp=84907550410&partnerID=8YFLogxK
U2 - 10.1001/jamaneurol.2014.1214
DO - 10.1001/jamaneurol.2014.1214
M3 - Article
C2 - 25023276
AN - SCOPUS:84907550410
SN - 2168-6149
VL - 71
SP - 1102
EP - 1110
JO - JAMA Neurology
JF - JAMA Neurology
IS - 9
ER -